Grail’s stock was the Nasdaq’s biggest loser Friday, after a key trial of its Galleri early-detection cancer test failed to meet its primary endpoint.
Markets
About Us
Contact Us
- 333, Pali Pathar, Khar West, Mumbai, Maharashtra 400052
- Pjazza Mifsud Bonnici, Marsascala, Malta
- info@markettrade.live
- +919769768500
